Patisiran
Oligonucleotide
Overview
Patisiran is a oligonucleotide active pharmaceutical ingredient (ChEMBL CHEMBL3989987).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Patisiran expires 27 Aug 2035 and exclusivity 13 Jan 2026. Generic API sourcing typically opens up once these lapse.
Verified Supplier Partner
Do you supply Patisiran? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.